Drug General Information |
Drug ID |
D05OMT
|
Former ID |
DCL000574
|
Drug Name |
MK-8033
|
Drug Type |
Small molecular drug
|
Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1]
|
Company |
Merck
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C25H21N5O3S
|
Canonical SMILES |
CN1C=C(C=N1)C2=CN=C3C=CC4=C(C=C(C=C4)CS(=O)(=O)NCC5=CC=<br />CC=N5)C(=O)C3=C2
|
InChI |
1S/C25H21N5O3S/c1-30-15-20(13-28-30)19-11-23-24(27-12-19)8-7-18-6-5-17(10-22(18)25(23)31)16-34(32,33)29-14-21-4-2-3-9-26-21/h2-13,15,29H,14,16H2,1H3
|
InChIKey |
VMJFTOSOFDEKTM-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
92392476, 120180975, 137318364, 137776016, 152258528, 160647362, 164041739, 164148325, 164156013, 172650675, 176250130, 185990466, 198946654, 215784726, 223626255, 224235397, 226728900, 249046422, 252479824
|
Target and Pathway |
Target(s) |
Hepatocyte growth factor receptor |
Target Info |
Inhibitor |
[2]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
Endocytosis
|
PI3K-Akt signaling pathway
|
Axon guidance
|
Focal adhesion
|
Adherens junction
|
Bacterial invasion of epithelial cells
|
Epithelial cell signaling in Helicobacter pylori infection
|
Malaria
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Renal cell carcinoma
|
Melanoma
|
Central carbon metabolism in cancer
|
Pathway Interaction Database
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
Arf6 signaling events
|
Signaling events mediated by TCPTP
|
Posttranslational regulation of adherens junction stability and dissassembly
|
Direct p53 effectors
|
Syndecan-1-mediated signaling events
|
Stabilization and expansion of the E-cadherin adherens junction
|
a6b1 and a6b4 Integrin signaling
|
FGF signaling pathway
|
Regulation of retinoblastoma protein
|
Reactome
|
Sema4D mediated inhibition of cell attachment and migration
|
WikiPathways
|
TGF beta Signaling Pathway
|
Signaling of Hepatocyte Growth Factor Receptor
|
Focal Adhesion
|
Extracellular vesicle-mediated signaling in recipient cells
|
Signaling Pathways in Glioblastoma
|
miR-targeted genes in squamous cell - TarBase
|
miR-targeted genes in muscle cell - TarBase
|
miR-targeted genes in lymphocytes - TarBase
|
miR-targeted genes in epithelium - TarBase
|
Semaphorin interactions
|
References |
REF 1 | ClinicalTrials.gov (NCT00559182) A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001). U.S. National Institutes of Health. |
---|
REF 2 | A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. |